Institution
Pierre-and-Marie-Curie University
Education•Paris, France•
About: Pierre-and-Marie-Curie University is a education organization based out in Paris, France. It is known for research contribution in the topics: Population & Raman spectroscopy. The organization has 34448 authors who have published 56139 publications receiving 2392398 citations.
Papers published on a yearly basis
Papers
More filters
••
Medical University of Vienna1, Chapel Allerton Hospital2, University of California3, University of Amsterdam4, University of Münster5, University of Washington6, University of Texas Health Science Center at Houston7, University of Rochester Medical Center8, Charité9, National Autonomous University of Mexico10, Sofia University11, Oregon Health & Science University12, Ghent University Hospital13, Pierre-and-Marie-Curie University14, Chung Shan Medical University15, Leiden University Medical Center16
TL;DR: The task force defined the treatment target for SpA as remission or, alternatively, low disease activity, being aware that the evidence base is not strong and needs to be expanded by future research.
Abstract: Background Therapeutic targets have been defined for diseases like diabetes, hypertension or rheumatoid arthritis and adhering to them has improved outcomes. Such targets are just emerging for spondyloarthritis (SpA). Objective To define the treatment target for SpA including ankylosing spondylitis and psoriatic arthritis (PsA) and develop recommendations for achieving the target, including a treat-to-target management strategy. Methods Based on results of a systematic literature review and expert opinion, a task force of expert physicians and patients developed recommendations which were broadly discussed and voted upon in a Delphi-like process. Level of evidence, grade and strength of the recommendations were derived by respective means. The commonalities between axial SpA, peripheral SpA and PsA were discussed in detail. Results Although the literature review did not reveal trials comparing a treat-to-target approach with another or no strategy, it provided indirect evidence regarding an optimised approach to therapy that facilitated the development of recommendations. The group agreed on 5 overarching principles and 11 recommendations; 9 of these recommendations related commonly to the whole spectrum of SpA and PsA, and only 2 were designed separately for axial SpA, peripheral SpA and PsA. The main treatment target, which should be based on a shared decision with the patient, was defined as remission, with the alternative target of low disease activity. Follow-up examinations at regular intervals that depend on the patient9s status should safeguard the evolution of disease activity towards the targeted goal. Additional recommendations relate to extra-articular and extramusculoskeletal aspects and other important factors, such as comorbidity. While the level of evidence was generally quite low, the mean strength of recommendation was 9–10 (10: maximum agreement) for all recommendations. A research agenda was formulated. Conclusions The task force defined the treatment target as remission or, alternatively, low disease activity, being aware that the evidence base is not strong and needs to be expanded by future research. These recommendations can inform the various stakeholders about expert opinion that aims for reaching optimal outcomes of SpA.
419 citations
••
TL;DR: The DNA sequence of the wild type and mutated introns as well as their flanking exons in the yeast mitochondrial gene specifying cytochrome b, and a trans-acting protein "mRNA maturase" responsible for splicing and maturation of cy tochrome b mRNA are determined.
418 citations
••
University of New South Wales1, University of Göttingen2, Pierre-and-Marie-Curie University3, Australian National University4, Clausthal University of Technology5, Kyoto University6, Eindhoven University of Technology7, University of Southern Mississippi8, Stellenbosch University9, Commonwealth Scientific and Industrial Research Organisation10, University of Queensland11, University of Sydney12
TL;DR: In this article, the authors comprehensively reviewed the kinetics and mechanism of dithiobenzoate-mediated Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerizations, which exhibit nonideal kinetic behavior, such as induction periods and rate retardation.
Abstract: Investigations into the kinetics and mechanism of dithiobenzoate-mediated Reversible Addition-Fragmentation Chain Transfer (RAFT) polymerizations, which exhibit nonideal kinetic behavior, such as induction periods and rate retardation, are comprehensively reviewed. The appreciable uncertainty in the rate coefficients associated with the RAFT equilibrium is discussed and methods for obtaining RAFT-specific rate coefficients are detailed. In addition, mechanistic studies are presented, which target the elucidation of the fundamental cause of rate retarding effects. The experimental and theoretical data existing in the literature are critically evaluated and apparent discrepancies between the results of different studies into the kinetics of RAFT polymerizations are discussed. Finally, recommendations for further work are given. (c) 2006 Wiley Periodicals, Inc.
418 citations
••
University of Pennsylvania1, Pierre-and-Marie-Curie University2, University of Cambridge3, Leiden University Medical Center4, Wellcome Trust Sanger Institute5, British Heart Foundation6, University of Glasgow7, Glasgow Clinical Research Facility8, International Centre for Diarrhoeal Disease Research, Bangladesh9, University of Michigan10, University of Lübeck11, Copenhagen University Hospital12, University of Copenhagen13, National Institutes of Health14, Pennsylvania State University15, University of Hamburg16, Pasteur Institute17, University of Strasbourg18, University of Toulouse19, Ludwig Maximilian University of Munich20, University of Insubria21, Queen's University Belfast22, National Institute for Health Research23, Technische Universität München24, Harvard University25, Washington University in St. Louis26
TL;DR: In this paper, the authors identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in SCARB1, the gene encoding SR-BI.
Abstract: Scavenger receptor BI (SR-BI) is the major receptor for high-density lipoprotein (HDL) cholesterol (HDL-C). In humans, high amounts of HDL-C in plasma are associated with a lower risk of coronary heart disease (CHD). Mice that have depleted Scarb1 (SR-BI knockout mice) have markedly elevated HDL-C levels but, paradoxically, increased atherosclerosis. The impact of SR-BI on HDL metabolism and CHD risk in humans remains unclear. Through targeted sequencing of coding regions of lipid-modifying genes in 328 individuals with extremely high plasma HDL-C levels, we identified a homozygote for a loss-of-function variant, in which leucine replaces proline 376 (P376L), in SCARB1, the gene encoding SR-BI. The P376L variant impairs posttranslational processing of SR-BI and abrogates selective HDL cholesterol uptake in transfected cells, in hepatocyte-like cells derived from induced pluripotent stem cells from the homozygous subject, and in mice. Large population-based studies revealed that subjects who are heterozygous carriers of the P376L variant have significantly increased levels of plasma HDL-C. P376L carriers have a profound HDL-related phenotype and an increased risk of CHD (odds ratio = 1.79, which is statistically significant).
417 citations
••
TL;DR: A substantial proportion of patients with NAFL can progress towards well-defined NASH with bridging fibrosis, especially if metabolic risk factors deteriorate, and current monitoring practices of these patients should be revised.
417 citations
Authors
Showing all 34671 results
Name | H-index | Papers | Citations |
---|---|---|---|
Zhong Lin Wang | 245 | 2529 | 259003 |
Guido Kroemer | 236 | 1404 | 246571 |
Krzysztof Matyjaszewski | 169 | 1431 | 128585 |
J. E. Brau | 162 | 1949 | 157675 |
E. Hivon | 147 | 403 | 118440 |
Kazuhiko Hara | 141 | 1956 | 107697 |
Simon Prunet | 141 | 434 | 96314 |
H. J. McCracken | 140 | 579 | 71091 |
G. Calderini | 139 | 1734 | 102408 |
Stefano Giagu | 139 | 1651 | 101569 |
Jean-Paul Kneib | 138 | 805 | 89287 |
G. Marchiori | 137 | 1590 | 94277 |
J. Ocariz | 136 | 1562 | 95905 |
Jean-Marie Tarascon | 136 | 853 | 137673 |
Alexis Brice | 135 | 870 | 83466 |